Ekaterina79/iStock via Getty Images
- Johnson & Johnson (NYSE:JNJ) said on Tuesday that it is seeking U.S. FDA approval for an expanded label of its antipsychotic drug, Capylta (lumateperone), to prevent a relapse in schizophrenia.
- Capylta is already approved by the FDA for treating schizophrenia and for managing depressive episodes linked to bipolar I or II disorder as an adjunctive and monotherapy in adults.
More on J&J
- Johnson & Johnson: Patience Will Be Rewarded
- Johnson & Johnson: Undervalued Dividend King With 65% Upside Potential
- Johnson & Johnson (JNJ) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
- Leaked memo reportedly shows biotech lobby group’s opposition to RFK Jr.
- US judge halts Trump administration move to layoff HHS employees